Tacrolimus treatment for relapsing-remitting chronic inflammatory demyelinating polyradiculoneuropathy: Two case reports

Wen-Jia Zhu, Yu-Wei Da, Hai Chen, Min Xu, Yan Lu, Li Di, Jian-Ying Duo

Abstract

BACKGROUND
This study describes the efficacy of a tacrolimus treatment regimen used to treat two patients with relapsing-remitting chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

CASE SUMMARY
Two patients (17-year-old female and 27-year-old male) were enrolled in the current study and were followed up for 12 mo. The first patient was administered tacrolimus (2 mg/d) for 12 mo and prednisolone (40 mg/d) for six months. The second patient was administered tacrolimus (3 mg/d) for six months. Both patients were followed up for 12 mo and the degree of recurrent weakness or normalized motor function was monitored. In addition, nerve conduction studies and tacrolimus levels were recorded. Following tacrolimus treatment, both patients showed marked improvement in clinical outcomes. In the first patient, prednisolone treatment was successfully withdrawn after six months. Sensory as well as motor nerve conduction velocities showed evident recovery following treatment. However, conduction velocities did not completely return to normal, suggesting that electrophysiological recovery can be slower than clinical recovery.

CONCLUSION
Neither patient exhibited any adverse effects due to the tacrolimus therapy. Therefore, tacrolimus can be effective for the treatment of patients with steroid-resistant CIDP.

Key Words: Chronic inflammatory demyelinating polyradiculoneuropathy; Prednisolone; Tacrolimus; Relapsing-remitting; Treatment; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
reviewed.

**Peer-review model:** Single blind

**Peer-review report’s scientific quality classification**
- Grade A (Excellent): A
- Grade B (Very good): B
- Grade C (Good): 0
- Grade D (Fair): 0
- Grade E (Poor): 0

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works upon this work non-commercially, the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/

**Received:** September 23, 2021

**Peer-review started:** September 23, 2021

**First decision:** October 22, 2021

**Revised:** November 5, 2021

**Accepted:** January 11, 2022

**Article in press:** January 11, 2022

**Published online:** February 16, 2022

**P-Reviewer:** Oley MH, Şurlin VM

**S-Editor:** Xing YX

**L-Editor:** A

**P-Editor:** Xing YX

---

**Core Tip:** Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated motor sensory neuropathy that is characterized by demyelination of the peripheral nerves and secondary axonal damage. Tacrolimus is mainly used in organ transplant patients and autoimmune diseases. Here, we investigate the efficacy of tacrolimus in two CIDP patients. Our results demonstrate the efficacy of tacrolimus treatment without significant adverse events. Therefore, tacrolimus can be used as an alternative treatment option if first line treatments are not effective or in refractory CIDP patients.

**Citation:** Zhu WJ, Da YW, Chen H, Xu M, Lu Y, Di L, Duo JY. Tacrolimus treatment for relapsing-remitting chronic inflammatory demyelinating polyradiculoneuropathy: Two case reports. *World J Clin Cases* 2022; 10(5): 1709-1715

**URL:** https://www.wjgnet.com/2307-8960/full/v10/i5/1709.htm

**DOI:** dx.doi.org/10.12998/wjcc.v10.i5.1709

---

**INTRODUCTION**

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated motor sensory neuropathy that is characterized by the demyelination of peripheral nerves and secondary axonal damage, and CIDP patients usually present with numbness and weakness of the extremities as well as a loss of reflexes. The exact pathogenesis of CIDP is not fully understood, but it involves an attack of the myelin sheath by components of both cellular and humoral immunity, ultimately leading to demyelination of nerve fibers.

There are several treatment options for CIDP including plasma exchange or the administration of corticosteroids (CS) and intravenous immunoglobulin (IVIg). The failure of first-line treatment strategies to obtain satisfactory outcomes can lead to the consideration of immunosuppressive agents. Immunosuppressive agents include azathioprine, methotrexate, interferon alpha (IFN-α), cyclosporine (CyA), cyclophosphamide, mycophenolate mofetil, rituximab and stem cell transplantation. Accumulating evidence has demonstrated that CyA, a calcineurin inhibitor, can selectively inhibit cytokines produced by helper T cells with a quick onset of action. However, CyA has also been associated with side effects that may include nephrotoxicity. Tacrolimus, another calcineurin inhibitor, is more bioavailable with a faster onset of action and lower nephrotoxicity than CyA. Tacrolimus has been widely used in organ transplantation and for the treatment of autoimmune diseases.

In 1998, Ahlmén et al. reported the treatment of a patient with CIDP using a combination of glucocorticoids and tacrolimus. However, detailed information regarding the efficacy and safety of tacrolimus in CIDP remains unknown. In this study, the clinical response and follow up evaluation of two CIDP patients treated with tacrolimus were reported.

---

**CASE PRESENTATION**

**Chief complaints**

**Case 1:** A 17-year-old female was hospitalized with recurrent episodes of numbness and weakness of limbs occurring over the previous 11 mo.

**Case 2:** A 27-year-old male was admitted to our department complaining of recurrent weakness and numbness in the limbs for 60 mo.

**History of present illness**

**Case 1:** In December 2016, the patient presented with numbness in both hands, weakness in the upper extremities, difficulty combing her hair, and difficulty dressing. The patient’s symptoms presumably began after she suffered from a common cold. In April 2017, her weakness worsened, and the patient could no longer lift her upper extremities and had trouble sitting upright. The numbness in both hands gradually...
progressed toward the proximal extremities. Upon admission, the patient was diagnosed with CIDP at her local hospital, and she was administered methylprednisolone (1000 mg/d for 3 d) and IVIg (0.4/kg/d for 5 d; Table 1). Following treatment, her symptoms subsided and she was discharged with no follow-up treatment. In July 2017, the patient presented with another episode of finger numbness and extremity weakness. After three days, the patient could not walk, and she was admitted to her local hospital. The patient was treated with IVIg (0.4/kg/d for 5 d) and her condition improved. Then, in November 2017 (11 mo after initial onset of symptoms), the patient presented with another CIDP episode and was admitted to our inpatient department one week after symptom onset.

**Case 2:** The patient presented with gradually progressive numbness and weakness in his extremities and was diagnosed with relapsing-remitting CIDP in February 2014. The patient was treated with multiple courses of IVIg (0.4/kg/d for 5 d, \( n = 12 \)) and methylprednisolone (1000 mg/d for 3 d) therapy with subsequent dosage reductions. During the steroid treatment periods, the patient’s weight increased from 70 kg to 103 kg [body mass index (BMI) of 30.86] and he developed secondary diabetes, hypertension, and hyperlipidemia. In October 2018, he again developed weakness in his extremities that gradually worsened.

**History of past illness**

**Cases 1 and 2:** The patient used to be in a good health and had no previous medical history.

**Personal and family history**

**Cases 1 and 2:** There were no negative personal habits or customs, and no special family history to note.

**Physical examination**

**Case 1:** The patient showed proximal extremity muscle strength values of 2-3 out of 5, distal extremity strength values of 3-4 out of 5, and an absence of tendon reflexes. However, her superficial/deep sensation was normal.

**Case 2:** The physical examination revealed obesity, an inability to walk on the toes, an inability to squat, a proximal/distal extremity muscle strength of 3 out of 5, and the absence of tendon reflexes as well as sensory anesthesia.

**Laboratory examinations**

**Case 1:** Lumbar puncture was performed and the results showed an elevated protein level (59 mg/dL). Routine blood, urine, and stool examinations were normal. Thyroid function, infection, immune findings (ESR, anti-nuclear antibody spectrum, anti-neutrophil cytoplasmic antibody, and anti-cardiolipin antibodies) and tumor screening results were normal. Immunofixation electrophoresis and anti-ganglioside ester antibodies were absent. Nerve conduction velocities were recorded.

**Case 2:** Lumbar puncture results showed an elevated protein level (82 mg/dL). Routine blood, urine, and stool examinations were normal. Thyroid function, infection, immune findings (ESR, anti-nuclear antibody spectrum, anti-neutrophil cytoplasmic antibody, and anti-cardiolipin antibodies) and tumor screening results were normal. Immunofixation electrophoresis and anti-ganglioside ester antibodies were absent. Nerve conduction velocities were recorded.

**Imaging examinations**

**Case 1:** The brain and spinal MRI scan did not reveal any abnormalities. The chest and abdominal Computed tomography (CT) scans were normal.

**Case 2:** The brain and spinal MRI scan did not reveal any abnormalities. The chest CT scan was normal. The abdominal CT scan showed fatty liver disease.

**FINAL DIAGNOSIS**

The final diagnosis of both patients was relapsing-remitting CIDP.
Table 1 Clinical features and therapeutic status of two patients with chronic inflammatory demyelinating polyradiculoneuropathy

| Case | Sex/age | Disease Course (mo) | Number of recurrences | Pretreatment medication | Tacrolimus Dosage (mg/d) | Length of treatment (mo) | Therapeutic effect (ONLS score) |
|------|---------|---------------------|-----------------------|-------------------------|--------------------------|-------------------------|------------------------------|
| 1    | F/17    | 11                  | 4                     | IVIg; steroids           | 40 mg 4 wk, 35 mg 4 wk, 30 mg was associated with onset of symptoms | 2                       | 12                           | 1                            | 0                            |
| 2    | M/27    | 60                  | 4                     | IVIg; steroids           | -                        | 3                       | 6                           | 2                            | 0                            |

ONLS: Overall neuropathy limitation scale; IVIg: Intravenous immunoglobulin.

**TREATMENT**

**Case 1**
Following admission, the patient’s weakness continued to progress and she was treated with IVIg (0.4/kg/d for 5 d) for the third time. Her extremity weakness and numbness quickly improved. However, her weakened left upper extremity and absence of right knee reflexes persisted. To prevent recurrence, oral prednisone (40 mg/d, reduced by 5 mg per month) was prescribed in November 2017.

**Case 2**
The patient could not continue steroid pulse therapy or the expensive IVIg treatments. Therefore, oral tacrolimus (3 mg/d) was administered for six months, and his body weight was strictly controlled.

**OUTCOME AND FOLLOW-UP**

**Case 1**
In January 2018, the prednisone dose was reduced to 30 mg, but the patient had gained 12 kg (BMI of 26.67). Then, she developed bilateral fingertip numbness and weakness for the fourth time. Physical examination revealed bilateral digital opposition, an extensor strength of 4 out of 5, and extremity tendon reflex attenuation. Other physical examination findings were normal. The patient was treated with tacrolimus (2 mg/d) and prednisone (40 mg/d) was added to her treatment regimen. During treatment, the serum concentration of tacrolimus fluctuated between 1.6 and 2.9 ng/μL (Table 1). Following the initiation of treatment with tacrolimus, the numbness disappeared in the second week, and prednisone was reduced by 5 mg every two weeks. In April 2018, prednisone was decreased to 15 mg and then gradually reduced for discontinuation, but tacrolimus was maintained at 2 mg/d until the end of the 12-month treatment course (January 2019). Prior to treatment, the overall neuropathy limitation scale (ONLS)[9] score was 1 point and it improved to 0 points after six months of treatment (Table 1). In addition, nerve conduction studies were recorded before and after treatment (Table 2). At the one-year follow-up appointment in January 2019, the patient was asymptomatic and the sensory as well as motor nerve conduction velocities had recovered, but did not completely return to normal, suggesting that electrophysiological recovery can be slower than clinical recovery (Table 2).

**Case 2**
After two months, the patient's weight dropped to 83 kg, and the extremity weakness was markedly improved. His diabetes, hypertension, and hyperlipidemia were controlled with medication. Physical examination revealed symmetrical biceps muscle strength and a finger extension strength ratio of 4/5, a finger abduction/adduction muscle strength of 5/5, a hip flexion and toe dorsiflexion strength ratio of 4/5, muscle strength of 5/5 in the other extremities, and the absence of tendon reflexes. Prior to tacrolimus treatment, the ONLS scores were 2 points, which improved after six months of treatment (Table 1). During treatment, the serum concentration of tacrolimus fluctuated between 5.1 and 6.8 ng/μL. At the one-year follow-up...
Zhu WJ et al. Efficacy of tacrolimus for CIDP

Table 2 Comparison of nerve conduction velocities before and after treatment in both patients

| Nerve       | Case 1 (one-year) | Case 2 (one-year) |
|-------------|-------------------|-------------------|
|             | Before            | After             | Before            | After             |
| MNCV Median | 5.9               | 4.7               | 7.7               | 6.73              |
| Velocity (m/s) | 22               | 35               | 28               | 38.6              |
| Tibial Distal latency (ms) | 6.8               | 7.3               | 8.2               | 8.19              |
| Velocity (m/s) | 42               | 43               | 45               | 35               |
| SNCV Median | Not elicited      | 2.9               | Not elicited      | 3.85              |
| Velocity (m/s) | Not elicited     | 47               | Not elicited      | 35.8              |
| Tibial Distal latency (ms) | 5.5               | Not performed    | Not elicited      | Not performed     |
| Velocity (m/s) | 30               | Not performed    | Not elicited      | Not performed     |

MNCV: Motor nerve conduction velocity; SNCV: Sensory nerve conduction velocity.

appointment, the sensory and motor nerve conduction velocities had recovered but did not completely return to normal, supporting the suggestion that electrophysiological recovery is slower than clinical recovery (Table 2).

DISCUSSION

In this study, two patients were clinically diagnosed with relapsing-remitting CIDP characterized by extremity numbness and weakness, electrophysiological findings consistent with demyelinating peripheral neuropathy, and lumbar puncture findings indicative of cerebrospinal fluid protein-cell separation. Both patients were young and childless (17 and 27 years of age), and the disease courses were 11 and 60 mo in patients 1 and 2, respectively. All other related diseases were excluded.

At the time of admission, both patients experienced CIDP symptoms that had recurred for the fourth time. The clinical features of case 1 were characterized by rapid progression after each recurrence. Following CS and IVIg treatment, her disability score improved by 4 points within five to seven days. However, the patient experienced weight gain following prednisone (40 mg/d) treatment and therefore she disliked the option of long-term CS use. Likewise, the second patient (case 2) developed obesity, diabetes, hypertension, and hyperlipidemia following long-term CS use. Their families could no longer afford the cost of IVIg and plasma exchange. Therefore, a quick-onset non-hormonal immunosuppressive agent was selected.

Ahlmén et al[15] used tacrolimus (also known as FK506) in 1998 to treat a 28-year-old woman with relapsing-remitting CIDP. In that particular patient, high-dose IVIg, cyclophosphamide, and azathioprine were ineffective. She had a favorable outcome with high-dose prednisone but she relapsed after discontinuation of the prednisone. Reduction therapy involving a combination of plasma exchange and a high dose of prednisone (80 mg/d) was effective, but the patient developed steroid myopathy. Therefore, she was administered a high dose of tacrolimus (0.42 mg/BMI/d) that was later reduced to 0.08 mg/BMI/d after 1.5 years, and prednisone (40 mg/d) was discontinued after the first six months. This treatment course had a favorable outcome, and the patient did not relapse within the one year of observation. Nevertheless, that patient developed side effects including diarrhea and hand tremors during the high-dose tacrolimus treatment course, but those symptoms disappeared when the tacrolimus dose was reduced[15].

The combination of tacrolimus and FK506 binding protein (FKBP) forms the FK506-FKBP-12 complex, which can prevent T cell proliferation, decrease T-cell mediated tissue damage, and play an immunosuppressive role through the inhibition of various lymphocyte products, such as IL-2[16]. Tacrolimus has been widely used in organ transplantation and may be an effective treatment strategy for CIDP patients. However, several organ transplant patients using tacrolimus developed reversible demyelinating peripheral neuropathy[17-19]. Nevertheless, those symptoms were observed in only 3% of organ transplant patients, and may be attributed to the high doses of tacrolimus that were administered (5-10 mg/d)[20].
In this study, both patients were young adults and childless. Due to possible reproductive toxicity, cyclophosphamide and azathioprine were not optimal treatment options in these younger patients[21,22]. Therefore, the patients preferred treatment with tacrolimus due to its relatively mild side effects and quick onset of action. Among the nonhormonal immunosuppressive agents, tacrolimus has the fastest onset of action [11,13]. In this study, case 2 used a single dose of tacrolimus (3 mg/d) for six months, and the severity of extremity weakness was significantly improved. On the other hand, case 1 used a slightly lower dose of tacrolimus (2 mg/d) for 12 mo. In case 1, although the serum concentration of tacrolimus was lower (fluctuating from 1.6 to 2.9 ng/μL), we were still able to reduce the concentration of prednisone and prevent side effects attributed to prolonged CS treatment. However, this suggests that the serum concentration of tacrolimus is not the only factor that determines the efficacy of treatment, but this point will be addressed in future studies.

CONCLUSION

In conclusion, these results demonstrate the efficacy and safety of low-dose tacrolimus in the treatment of CIDP if first-line treatment options were ineffective or contraindicated. Nevertheless, future multi-center studies that enroll a greater number of patients will be necessary to fully evaluate the role of tacrolimus in the treatment of CIDP.

ACKNOWLEDGEMENTS

Thanks due to the two young patients’ support and the trust in our hospital.

REFERENCES

1 Köller H, Kieserie BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005; 352: 1343-1356 [PMID: 15800230 DOI: 10.1056/NEJMra041347]
2 Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010; 9: 402-412 [PMID: 20298964 DOI: 10.1016/S1474-4422(10)70041-7]
3 Koike H, Katsumo M. Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy. Neurrol Ther 2020; 9: 213-227 [PMID: 32410146 DOI: 10.1007/s40120-020-00190-8]
4 Van den Bergh PY, Hudden RD, Bouche P, Comblath DR, Hahn A, Illa I, Koski CL, Léger JM, Nobile-Orazio E, Pollard J, Sommer C, van Doorn PA, van Schaik IN; European Federation of Neurological Societies, Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol 2010; 17: 356-363 [PMID: 20456730 DOI: 10.1111/j.1468-1331.2009.02930.x]
5 Dyck PJB, Tracy JA. History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Mayo Clin Proc 2018; 93: 777-793 [PMID: 29866282 DOI: 10.1016/j.mayocp.2018.03.026]
6 De Sousa EA, Brannagan TH 3rd. Diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. Curr Treat Options Neurol 2006; 8: 91-103 [PMID: 16464406 DOI: 10.1007/s11940-006-0001-2]
7 Rajabally YA. Unconventional treatments for chronic inflammatory demyelinating polyneuropathy. Neurodegener Dis Manag 2017; 7: 331-342 [PMID: 29043889 DOI: 10.2217/nmt-2017-0017]
8 Hodgkinson SJ, Pollard JD, McLeod JG. Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 1999; 63: 327-330 [PMID: 2341846 DOI: 10.1136/jnnp.53.4.327]
9 Barnett MH, Pollard JD, Davies L, McLeod JG. Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1998; 21: 454-460 [PMID: 9533779 DOI: 10.1002/(sici)1097-4598(199804)21:4<454::aid-mus3>3.0.co;2-8]
10 Visudtibhan A, Chiemchunya S, Visudhiphan P. Cyclosporine in chronic inflammatory demyelinating polyradiculoneuropathy. Pediatr Neurol 2005; 33: 368-372 [PMID: 16243226 DOI: 10.1016/j.pediatrneurol.2005.05.015]
11 House AA, Elmasiri M, Denesyk K, Luke PP, Muirhead N, Rehman F, Boudville N, Jevnikar AM. Apparent low absorbers of cyclosporine microemulsion have higher requirements for tacrolimus in renal transplantation. Clin Transplant 2007; 21: 518-522 [PMID: 17645712 DOI: ]
12 Lee J. Use of antioxidants to prevent cyclosporine a toxicity. *Toxicol Res* 2010; 26: 163-170 [PMID: 24278520 DOI: 10.5487/TR.2010.26.3.163]

13 Kamel M, Kadian M, Srinivas T, Taber D, Posadas Salas MA. Tacrolimus confers lower acute rejection rates and better renal allograft survival compared to cyclosporine. *World J Transplant* 2016; 6: 697-702 [PMID: 28058820 DOI: 10.5500/wjt.v6.i4.697]

14 Dheer D, Jyoti, Gupta PN, Shankar R. Tacrolimus: An updated review on delivering strategies for multifarious diseases. *Eur J Pharm Sci* 2018; 114: 217-227 [PMID: 29277665 DOI: 10.1016/j.ejps.2017.12.017]

15 Ahlmén J, Andersen O, Hallgren G, Peilot B. Positive effects of tacrolimus in a case of CIDP. *Transplant Proc* 1998; 30: 4194 [PMID: 9865344 DOI: 10.1016/s0041-1345(98)01389-x]

16 Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. *Immunol Today* 1992; 13: 136-142 [PMID: 1374612 DOI: 10.1016/0167-5699(92)90111-J]

17 Renard D, Gauthier T, Venetz JP, Bueclin T, Kuntzer T. Late onset tacrolimus-induced life-threatening polyneuropathy in a kidney transplant recipient patient. *Clin Kidney J* 2012; 5: 323-326 [PMID: 25874089 DOI: 10.1093/ckj/sfs067]

18 Mahdi-Rogers M, van Doorn PA, Hughes RA. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. *Cochrane Database Syst Rev* 2013; CD003280 [PMID: 23771584 DOI: 10.1002/14651858.CD003280.pub4]

19 Hergüner MO, Incecik F, Altunbaşak S. Cyclosporin treatment in three children with chronic inflammatory demyelinating neuropathy. *Pediatr Neurol* 2009; 41: 223-225 [PMID: 19664543 DOI: 10.1016/j.pediatrneurol.2009.03.016]

20 Wilson JR, Conwit RA, Eidelman BH, Starzl T, Abu-Elmagd K. Sensorimotor neuropathy resembling CIDP in patients receiving FK506. *Muscle Nerve* 1994; 17: 528-532 [PMID: 7512691 DOI: 10.1002/mus.880170510]

21 Moon JI, Park SG, Cheon KO, Kim SI, Kim YS, Park YW, Park K. Pregnancy in renal transplant patients. *Transplant Proc* 2000; 32: 1869-1870 [PMID: 11119976 DOI: 10.1016/s0041-1345(00)01469-x]

22 Srinivas M, Agarwala S, Datta Gupta S, Das SN, Jha P, Misro MM, Mitra DK. Effect of cyclosporine on fertility in male rats. *Pediatr Surg Int* 1998; 13: 388-391 [PMID: 9639624 DOI: 10.1007/s003830050346]
